AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05222334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrafascial interscalene brachial plexus block
Description: After sterilization of skin with povidone-iodine (betadine) and skin infiltration with 1-3ml lidocaine 1%, interscalene brachial plexus block will be performed using an ultrasound machine (Phillips Cx-50,Amsterdam, Netherlands) with a linear probe (L12-3 MHz) will be used in both groups. The US transducer will be placed under aseptic fashion on the lateral side of the neck at the cricoid cartilage level to view three hypoechoic structures, that represent the roots of the brachial plexus.~The two outermost nerve roots (C5 and C6) between the anterior and the middle scalene muscles will be identified and the local anesthetic (10 ml 0.5% bupivacaine) is then injected, so that spread will be seen immediately between the C5 and the C6 nerve roots.
Study NCT05222334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extrafascial interscalene brachial plexus block group
Description: Final needle tip position will be 4 mm lateral to the brachial plexus sheath, at a level equidistant between C5 and C6 roots. The distance of 4 mm is chosen according to the calculated success rate over 90% reported. the local anesthetic (10 ml 0.5% bupivacaine) is then injected
Study NCT05222334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine
Study NCT05015933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pump refill procedure at home
Description: Implantable pump refill is performed at home
Study NCT05358106 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AntiBKV
Description: AntiBKV neutralising antibody
Study NCT05358106 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution with no active ingredients
Study NCT05279001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablet
Description: Orally administered, twice a day
Study NCT06265064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: STOP-Bang score >= 3 with factors predicting difficult intubation
Description: patients with STOP-Bang score >= 3 with Mallampati score ≥ 3 or neck circumference >42 cm or mentothyroid distance \<6 cm
Study NCT05493215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Therapeutic drug level monitoring with plans to increase to adjust drug dosage based on levels and patient symptoms.
Study NCT04985968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobitolimod 250 mg
Description: Rectal administration
Study NCT04985968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobitolimod 500 mg
Description: Rectal administration
Study NCT04985968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rectal administration
Study NCT06294054 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: neoadjuvant chemotherapy with cisplatine
Description: Blood from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
Study NCT05253820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: distal radial approach
Description: coronary diagnosis and intervention via distal vs conventional radial approach
Study NCT05253820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional radial access
Description: conventional radial access
Study NCT05625308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate, Folic acid, Vitamin B12, and Hyaluronic Acid
Description: One tablet per day containing 200 mg of EGCG, 400 mcg of Folic Acid, 1 mg of Vitamin B12 and 50 mg of Hyaluronic Acid.
Study NCT04979650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone succinate
Description: 1 gram of methylprednisolone succinate within 500 ccs of normal saline
Study NCT04979650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone succinate
Description: 1 gram of methylprednisolone succinate within 500 ccs of normal saline
Study NCT04979650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 500 g of normal saline without methylprednisolone succinate
Study NCT04979650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 500 g of normal saline without methylprednisolone succinate
Study NCT05463692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Camelia Cohort
Description: Through the HealthMpowerment (HMP) app tailored for women, we will be able to provide informational content, access to resources, PrEP locators and additional gamification features to optimally engage and retain our cohort, which may support linkage to PrEP care.
Study NCT05994196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimum, a secondary prioritization software of patients in the pediatric emergency department (ED)
Description: Optimum®'s purpose is to remove the mental load of prioritization from the Pediatric ED staff. The software first prioritizes the triage of new patients by the ED staff and the first evaluation of a new patient by the medical team. Optimum® then prioritizes blood sample collections and care (for nurses) and checks on imaging results, blood test results or an evaluation by a specialist (for physicians). Lastly, Optimum® prioritizes the final step in patient management by a senior physician, when appropriate.
Study NCT05663879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID120040002
Description: Drug: ID120040002
Study NCT05663879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound-X
Description: Drug: Compound-X
Study NCT05663879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: Placebo comparator
Study NCT05114239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol 0.25% Ophthalmic Solution
Description: Applied to treatment side prior to standard wound care
Study NCT05114239 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Wound Care
Description: Wound is washed twice a day with soap and then petrolatum and a bandage is applied.
Study NCT06109025 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FESIA GRASP
Description: The Fesia Grasp device is based on the superficial electrical stimulation of the forearm musculature to provoke flexion and extension movements of the wrist, thumb, index finger and fingers 3, 4 and 5.
Study NCT06109025 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VIRTUAL REHAB
Description: VirtualRehab is a therapeutic physical rehabilitation tool that uses virtual reality to provide therapy for patients with neurological or musculoskeletal disorders; providing a wide range of activities designed to improve mobility, coordination and strength.
Study NCT06109025 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: GLOBUS ELITE
Description: is an electro-stimulator designed for sport and fitness, but with special attention also for beauty treatments thanks to the new sequential stimulation currents, excellent for their draining effects.
Study NCT05597462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride capsules
Description: Minocycline hydrochloride capsules, 40 mg will be administered orally once daily for 16 weeks.
Study NCT05597462 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be administered orally once daily for 16 weeks.
Study NCT05644860 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nanohybrid Compisite Group (Filtek Z250)
Description: Orthodontic brackets shall be bonded with Nano hybrid composite
Study NCT05644860 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Composite Group (Transbond XT)
Description: Patients in which brackets will be bonded with conventional composite resin (Transbond XT)
Study NCT05483634 — intervention group
Intervention type: DRUG
Intervention: Vaginal estrogen supplement
Description: Daily vaginal estrogen supplement, then twice per week. Continue for three months.
Study NCT05483634 — intervention group
Intervention type: PROCEDURE
Intervention: Platelet-rich plasma injection
Description: Monthly platelet-rich plasma injection for three months
Study NCT05560347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot water application
Description: Hot application is applied by contacting any part of the body with a temperature of 40-45 degrees. Hot application stimulates the touch receptors and has a vasodilation effect. Thermoreceptors in the foot are stimulated by applying heat to the feet, and this stimulation is thought to be effective in reducing the activation of the sympathetic nervous system and thus reducing pain.
Study NCT05045508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC-01 (varenicline 0.6mg/ml) nasal spray
Description: OC-01 nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production and bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
Study NCT05045508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) Nasal Spray
Description: Placebo (vehicle) nasal spray \[control\]
Study NCT06202586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low FiO2
Description: FiO2 was 100% in two-lung ventilation during anesthesia induction and one-lung ventilation stage intraoperative. FiO2 was 30% in two-lung ventilation after pulmonary reexpansion. During 2 hours after extubation, oxygen was administered through a non-reabsorption mask (high concentration oxygen mask; Intersurgical Ltd, Wokingham, UK) with a respiratory sac in the post anesthesia care unit (PACU), FiO2 was 30% (2L oxygen +14L air per minute). If the subjects who need to be admitted to the intensive care unit (ICU) fail to resuscitate the extubation within a short time after surgery due to their condition and require prolonged respiratory support, FiO2 should be adjusted to 30% 2 hours after admission to the ICU, and respiratory support according to the routine ventilation strategy of ICU should be provided 2 hours later.
Study NCT06202586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high FiO2
Description: FiO2 was 100% in two-lung ventilation during anesthesia induction and one-lung ventilation stage intraoperative. FiO2 was 80% in two-lung ventilation after pulmonary reexpansion. During 2 hours after extubation, oxygen was administered through a non-reabsorption mask (high concentration oxygen mask; Intersurgical Ltd, Wokingham, UK) with a respiratory sac in the post anesthesia care unit (PACU), FiO2 was 80% (14L oxygen +2L air per minute). If the subjects who need to be admitted to the intensive care unit (ICU) fail to resuscitate the extubation within a short time after surgery due to their condition and require prolonged respiratory support, FiO2 should be adjusted to 80% 2 hours after admission to the ICU, and respiratory support according to the routine ventilation strategy of ICU should be provided 2 hours later.
Study NCT05515380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8-stage model based exercise program
Description: The experimental group would follow exercises related to 8 phases of tennis serve, which would be based on 8-stage model. The participants would follow this program for three days per week for 12 weeks.
Study NCT05515380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise program
Description: The control group would follow conventional exercise program advised by coaches. The participants of this group would also follow this program for three days per week for 12 weeks.
Study NCT04670588 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor DNA(ctDNA) level measurement
Description: The ctDNA level will be measured using the Signatera platform developed by Natera, Inc. Signatera is a patient-specific, tumor informed custom-built ctDNA monitoring assay.
Study NCT06319014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Modes
Description: Moderate intensity aerobic exercise Moderate intensity resistance exercise Moderate intensity combination exercise
Study NCT05751187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab was given as 200 milligrams (mg) via intravenous (IV) infusion over 30 minutes on Day 1 of each 21-day cycle.
Study NCT05751187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was given as 15 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle.
Study NCT05751187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed was given as 500 mg/m\^2 via intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle for 4-6 cycles.
Study NCT05751187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin was given as 75 mg/m\^2 via intravenous (IV) infusion (administered approximately 30 minutes after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.
Study NCT05751187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was given as Aare Under the Curve (AUC) 5 (5 mg/mL/min; over 15-60 min) via intravenous (IV) infusion (administered immediately after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.
Study NCT05751187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid 350-1000 μg
Description: Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
Study NCT05751187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12 1000 μg
Description: Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given on the same day as pemetrexed administration.
Study NCT05751187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, the day of, and the day after pemetrexed administration.
Study NCT05689996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone-Based Agent
Description: Ozone-based eye drops as adjuvant therapy in microbial keratitis
Study NCT04859907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clamp-like system
Description: Craniotomy closure
Study NCT04859907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plates and screws
Description: Craniotomy closure
Study NCT06169969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic therapy
Description: Kegel exercises
Study NCT05512884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speeded anomia therapy
Description: The speeded anomia therapy was introduced as RISP (Repeated, Increasingly Speeded Production) by Conroy et al. (2018). Participants are asked to name the picture presented to them before an auditory stimulus ('beep' sound) at the end of item presentation. In each session the allotted response time is gradually reduced. After an incorrect response, participants are asked to repeat the word three times.
Study NCT05536401 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: P200TE
Description: The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
Study NCT05536401 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Predicate Device
Description: The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
Study NCT04965818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib and Binimetinib
Description: Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle
Study NCT05661643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide capsule
Description: Temozolomide 200 mg/m2 is administered orally for 1-5 days of each cycle, and then canceled for 23 days (a total of 28 days is 1 cycle)
Study NCT05510388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygenation
Description: The patients receive oxygen flow of 6L/min for preoxygenation with an high-flow canular oxygenation device before losing of conscious. Then, the oxygen flow is adjusted to 60L/min with the oxygen concentration of 100% and the temperature of 37℃ until the end of procedure.
Study NCT05510388 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular nasal cannula oxygenation
Description: The patients receive an oxygen flow of 6L/min for preoxygenation with a disposal regular nasal cannula until the end of procedure.
Study NCT06324604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06324604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX-101
Description: MTX-101 (bispecific CD8 Treg modulator)
Study NCT04881981 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SCART radiation therapy
Description: We will deliver high dose radiation therapy using SCART method. Beam energies of 6Mv will be used. The high dose SCART therapy will be delivered using LINAC systems, as available and appropriate for each patient. The treatment plan used for each patient will be based on an analysis of the volumetric dose including DVH analyses of the PTV and critical normal structures.
Study NCT05339984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial hepatectomy (open approach)
Description: preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
Study NCT05339984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver transplantation
Description: preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
Study NCT05339984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portal vein embolization
Description: preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
Study NCT04881604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Compression Wrap
Description: Delivery, adaptation and guidance for daily use of the Adjustable Compression Wrap. (Ready Wrap® allows for easy use because to be pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compressive properties, it can be used as therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily.
Study NCT04881604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Sleeve
Description: Delivery, adaptation and guidance for daily use of the Compression sleeve. (Compression Sleeve is a mesh in the shape of a glove that provides compression on the fabrics needed to help control the volume of the limbs. Traditionally used for stage 2 of compressive therapy. The composition of the material is: 64% Nylon, 36% Elastane (Spandex) ).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily.
Study NCT05801744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Operant conditioning
Description: In this training, individuals with post-stroke hemiparesis are trained to increase the amount of reciprocal inhibition in their paretic leg. By increasing the amount of reciprocal inhibition, the paretic ankle in people post-stroke may exhibit less foot drop.
Study NCT06342271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic walking training
Description: Participants will receive Nordic walking training (to walk with poles) for 12 weeks, 3x/week.
Study NCT06342271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free Walking training
Description: Participants will receive Free walking training (to walk without poles) for 12 weeks, 3x/week.
Study NCT05552885 — intervention group
Intervention type: OTHER
Intervention: Evaluation
Description: The Standardized Mini Mental Test, The American National Institutes of Health Stroke Scale, the Figure of 8 Walk Test, the double-task octagonal gait test, the timed up-and-go test, the 10-meter walk test, and the modified four-square step test will be applied to the stroke patients.
Study NCT04818333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: Phase 1 Drug: SHR-A1811 There are four pre-defined dose regimens . Subjects will be enrolled with an initial dose Phase 2 Drug: SHR-A1811 Doses will be determined from Phase 1